Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology

Harris, 2002, Prostaglandins as modulators of immunity, Trends Immunol., 23, 144, 10.1016/S1471-4906(01)02154-8

Wada, 2007, Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products, J. Biol. Chem., 282, 22254, 10.1074/jbc.M703169200

Levin, 2002, Differential metabolism of dihomo-γ-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2, Biochem. J., 365, 489, 10.1042/bj20011798

Akaogi, 2006, Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy, Endocr. Metab. Immune Disord. Drug Targets, 6, 383, 10.2174/187153006779025711

Wan, 2007, Eicosanoids in asthma, Acta Paediatr. Taiwan., 48, 299

Dubinett, 2003, Cyclooxygenase-2 in lung cancer, Prog. Exp. Tumor Res., 37, 138, 10.1159/000071371

Chang, 2005, Differential regulation of cyclooxygenase 2 expression by small GTPases Ras, Rac1, and RhoA, J. Cell. Biochem., 96, 314, 10.1002/jcb.20568

Narumiya, 2001, Genetic and pharmacological analysis of prostanoid receptor function, J. Clin. Invest., 108, 25, 10.1172/JCI13455

Hirai, 2001, Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2, J. Exp. Med., 193, 255, 10.1084/jem.193.2.255

Monneret, 2001, Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor, Blood, 98, 1942, 10.1182/blood.V98.6.1942

Bos, 2004, Prostanoids and prostanoid receptors in signal transduction, Int. J. Biochem. Cell Biol., 36, 1187, 10.1016/j.biocel.2003.08.006

Bhattacharya, 1998, Nuclear localization of prostaglandin E2 receptors, Proc. Natl. Acad. Sci. U. S. A., 95, 15792, 10.1073/pnas.95.26.15792

Ide, 2003, Activation of nuclear receptors by prostaglandins, Thromb. Res., 110, 311, 10.1016/S0049-3848(03)00418-3

Yokomizo, 1997, A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis, Nature, 387, 620, 10.1038/42506

Yokomizo, 2000, A second leukotriene B4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders, J. Exp. Med., 192, 421, 10.1084/jem.192.3.421

Lynch, 1999, Characterization of the human cysteinyl leukotriene CysLT1 receptor, Nature, 399, 789, 10.1038/21658

Bäck, 2007, Leukotriene receptors: crucial components in vascular inflammation, Scientific World Journal, 7, 1422, 10.1100/tsw.2007.187

Boyce, 2007, Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation, Immunol. Rev., 217, 168, 10.1111/j.1600-065X.2007.00512.x

Burgermeister, 2003, Activation of cytosolic phospholipase A2 in human T-lymphocytes involves inhibitor-κB and mitogen-activated protein kinases, Eur. J. Pharmacol., 466, 169, 10.1016/S0014-2999(03)01492-4

Feldon, 2006, Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes, Am. J. Pathol., 169, 1183, 10.2353/ajpath.2006.060434

Mongini, 2007, COX-2 expression in B lymphocytes: links to vaccines, inflammation and malignancy, Clin. Immunol., 125, 117, 10.1016/j.clim.2007.07.013

Bernard, 2007, CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: implications for adjuvant activity and antibody production, Clin. Immunol., 125, 138, 10.1016/j.clim.2007.07.006

Harizi, 2005, The impact of eicosanoids on the cross talk between innate and adaptive immunity: the key role of dendritic cells, Tissue Antigens, 65, 507, 10.1111/j.1399-0039.2005.00394.x

Banchereau, 2005, Dendritic cells as therapeutic vaccines against cancer, Nat. Rev. Immunol., 5, 296, 10.1038/nri1592

Munz, 2005, Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity, J. Exp. Med., 202, 203, 10.1084/jem.20050810

Harizi, 2004, Inhibition of IL-6, TNF-α, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells, Cell. Immunol., 228, 99, 10.1016/j.cellimm.2004.04.003

Józefowski, 2003, Exogenous but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved, Int. Immunopharmacol., 3, 865, 10.1016/S1567-5769(03)00072-9

Fogel-Petrovic, 2004, Activated human dendritic cells express inducible cyclo-oxygenase and synthesize prostaglandin E2 but not prostaglandin D2, Immunol. Cell Biol., 82, 47, 10.1111/j.1440-1711.2004.01213.x

Harizi, 2003, Prostaglandins inhibit 5-lipoxygenase-activating protein expression and leukotriene B4 production from dendritic cells via an IL-10-dependent mechanism, J. Immunol., 170, 139, 10.4049/jimmunol.170.1.139

Harizi, 2004, Eicosanoids: an emerging role in dendritic cell biology, Arch. Immunol. Ther. Exp. (Warsz.), 52, 1

Gualde, 2004, Prostanoids and their receptors that modulate dendritic cell-mediated immunity, Immunol. Cell Biol., 82, 353, 10.1111/j.0818-9641.2004.01251.x

Harizi, 2001, Dendritic cells issued in vitro from bone marrow produce PGE2 that contributes to the immunomodulation induced by antigen-presenting cells, Cell. Immunol., 209, 19, 10.1006/cimm.2001.1785

Harizi, 2002, Dendritic cells produce eicosanoids, which modulate generation and functions of antigen-presenting cells, Prostaglandins Leukot. Essent. Fatty Acids, 66, 459, 10.1054/plef.2002.0383

Harizi, 2003, Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes, J. Leukoc. Biol., 73, 756, 10.1189/jlb.1002483

Vassiliou, 2003, Prostaglandin E2 inhibits TNF-α production in murine bone marrow-derived dendritic cells, Cell. Immunol., 223, 120, 10.1016/S0008-8749(03)00158-8

Kabashima, 2003, Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells, Nat. Med., 9, 744, 10.1038/nm872

Luft, 2002, Functionally distinct dendritic cell populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets, Blood, 100, 1362, 10.1182/blood-2001-12-0360

Robbiani, 2000, The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes, Cell, 103, 757, 10.1016/S0092-8674(00)00179-3

Scandella, 2002, Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells, Blood, 100, 1354, 10.1182/blood-2001-11-0017

Whittaker, 2000, Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostanoid production, J. Immunol., 165, 4298, 10.4049/jimmunol.165.8.4298

Józefowski, 2005, Leukotrienes modulate cytokine release from dendritic cells, Immunology, 116, 418, 10.1111/j.1365-2567.2005.02241.x

Kalinski, 1998, Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+ CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation, J. Immunol., 161, 2804, 10.4049/jimmunol.161.6.2804

Kalinski, 2001, Prostaglandin E2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer, Blood, 97, 3466, 10.1182/blood.V97.11.3466

Harizi, 2002, Cyclooxygenase-2-issued prostaglandin E2 enhances the production of endogenous IL-10, which down-regulates dendritic cell functions, J. Immunol., 168, 2255, 10.4049/jimmunol.168.5.2255

Aliberti, 2002, Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity, Nat. Immunol., 3, 76, 10.1038/ni745

Theiner, 2006, The mast cell mediator PGD2 suppresses IL-12 release by dendritic cells leading to Th2 polarized immune responses in vivo, Immunobiology, 211, 463, 10.1016/j.imbio.2006.05.020

Stafford, 2008, Prostaglandin E2 inhibits tumor necrosis factor-α RNA through PKA type I, Biochem. Biophys. Res. Commun., 366, 104, 10.1016/j.bbrc.2007.11.091

Shinomiya, 2001, Regulation of TNF-α and interleukin-10 production by prostaglandins I2 and E2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists, Biochem. Pharmacol., 61, 1153, 10.1016/S0006-2952(01)00586-X

Lee, 2008, Human follicular dendritic cells interact with T cells via expression and regulation of cyclooxygenases and prostaglandin E and I synthases, J. Immunol., 180, 1390, 10.4049/jimmunol.180.3.1390

Choudhry, 1999, PGE2 suppresses mitogen-induced Ca2+ mobilization in T cells, Am. J. Physiol., 277, R1741

Choudhry, 1999, PGE2-mediated inhibition of T cell p59(fyn) is independent of cAMP, Am. J. Physiol., 277, C302, 10.1152/ajpcell.1999.277.2.C302

Ruggeri, 2000, Polyamine metabolism in prostaglandin E2-treated human T lymphocytes, Immunopharmacol. Immunotoxicol., 22, 117, 10.3109/08923970009016410

Bryn, 2008, LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism, Int. Immunol., 20, 235, 10.1093/intimm/dxm134

Liu, 2008, Leukotriene B4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures, Blood, 111, 2693, 10.1182/blood-2007-08-102319

Luster, 2004, T-cell trafficking in asthma: lipid mediators grease the way, Nat. Rev. Immunol., 4, 711, 10.1038/nri1438

Ropper, 2002, Prostaglandin E2 and cAMP promote B lymphocyte class switching to IgG1, Immunol. Lett., 84, 191, 10.1016/S0165-2478(02)00185-2

Fedyk, 1996, Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells, Proc. Natl. Acad. Sci. U. S. A., 93, 10978, 10.1073/pnas.93.20.10978

Yakar, 2003, Prostaglandin E2 suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats, Ann. Surg. Oncol., 10, 469, 10.1245/ASO.2003.08.017

Walker, 2004, Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis, Immunology, 111, 298, 10.1111/j.1365-2567.2004.01810.x

Chen, 2007, Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor, J. Immunol., 179, 2766, 10.4049/jimmunol.179.5.2766

Holgate, 2003, Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling, J. Allergy Clin. Immunol., 111, S18, 10.1067/mai.2003.25

Parameswaran, 2002, Cysteinyl leukotrienes promote human airway smooth muscle migration, Am. J. Respir. Crit. Care Med., 166, 738, 10.1164/rccm.200204-291OC

Serhan, 2000, Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing, J. Exp. Med., 192, 1197, 10.1084/jem.192.8.1197

Serhan, 2000, Preventing injury from within, using selective cPLA2 inhibitors, Nat. Immunol., 1, 13, 10.1038/76865

Chiang, 2005, Anti-inflammatory circuitry: lipoxins, aspirin-triggered lipoxins and their receptor ALX, Prostaglandins Leukot. Essent. Fatty Acids, 73, 163, 10.1016/j.plefa.2005.05.003

Demeure, 1997, Prostaglandin E2 primes naïve T cells for the production of anti-inflammatory cytokines, Eur. J. Immunol., 27, 3526, 10.1002/eji.1830271254

Kuwabara, 2000, Effects of the second-generation leukotriene B4 receptor antagonist, LY293111Na, on leukocyte infiltration and collagen-induced arthritis in mice, Eur. J. Pharmacol., 402, 275, 10.1016/S0014-2999(00)00518-5

Tsuji, 1999, Involvement of leukotriene B4 in arthritis models, Life Sci., 64, PL51, 10.1016/S0024-3205(98)00556-6

Kim, 2006, A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis, J. Exp. Med., 203, 829, 10.1084/jem.20052349

Drazen, 1999, Treatment of asthma with drugs modifying the leukotriene pathway, N. Engl. J. Med., 340, 197, 10.1056/NEJM199901213400306

Serhan, 2008, Anti-inflammatory and proresolving lipid mediators, Annu. Rev. Pathol., 3, 279, 10.1146/annurev.pathmechdis.3.121806.151409

Levy, 2002, Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4), Nat. Med., 8, 1018, 10.1038/nm748

Levy, 2003, Exploring new approaches to the treatment of asthma: potential roles for lipoxins and aspirin-triggered lipid mediators, Drugs Today (Barc), 39, 373, 10.1358/dot.2003.39.5.740217

Krysan, 2006, The potential and rationale for COX-2 inhibitors in lung cancer, Anticancer. Agents Med. Chem., 6, 209, 10.2174/187152006776930882

Wang, 2004, Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferators-activated receptor delta, Cancer Cell, 6, 285, 10.1016/j.ccr.2004.08.011

Takaku, 2000, Suppression of intestinal polyposis in Apc(δ716) knockout mice by an additional mutation in the cytosolic phospholipase A2 gene, J. Biol. Chem., 275, 34013, 10.1074/jbc.C000586200

Tiano, 2002, Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis, Cancer Res., 62, 3395

Kawamori, 2005, Prostaglandin E receptor subtype EP1 deficiency inhibits colon cancer development, Carcinogenesis, 26, 353, 10.1093/carcin/bgh322

Park, 2007, Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice, Cancer Res., 67, 881, 10.1158/0008-5472.CAN-05-3767

Ding, 2005, A novel anti-pancreatic cancer agent, LY293111, Anticancer Drugs, 16, 467, 10.1097/00001813-200506000-00001

Paruchuri, 2006, Endogenous production of leukotriene D4 mediates autocrine survival and proliferation via CysLT1 receptor signalling in intestinal epithelial cells, Oncogene, 25, 6660, 10.1038/sj.onc.1209666

Avis, 2001, Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions, FASEB J., 15, 2007, 10.1096/fj.00-0866fje

Ohd, 2003, Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas, Gastroenterology, 124, 57, 10.1053/gast.2003.50011

Liu, 2001, Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice, J. Biol. Chem., 276, 18563, 10.1074/jbc.M010787200

Sumitani, 2001, Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production, J. Oral Pathol. Med., 30, 41, 10.1034/j.1600-0714.2001.300107.x

Pradono, 2002, Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth, Cancer Res., 62, 63

Backlund, 2008, Novel strategies for the treatment of lung cancer: modulation of eicosanoids, J. Clin. Oncol., 20, 825, 10.1200/JCO.2007.14.9583

Edelman, 2008, Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib+chemotherapy – Cancer and Leukemia Group B trial 30203, J. Clin. Oncol., 26, 848, 10.1200/JCO.2007.13.8081

Shen, 2007, Peroxisome proliferator-activated receptor γ agonists inhibit the proliferation and invasion of human colon cancer cells, Postgrad. Med. J., 83, 414, 10.1136/pmj.2006.052761

Yang, 2003, Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor, J. Clin. Invest., 111, 727, 10.1172/JCI16492

Sharma, 2003, Tumor cyclooxygenase 2-dependent suppression of dendritic cell function, Clin. Cancer Res., 9, 961

Pockaj, 2004, Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer, Ann. Surg. Oncol., 11, 328, 10.1245/ASO.2004.05.027

Khanapure, 2007, Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers, Curr. Top. Med. Chem., 7, 311, 10.2174/156802607779941314

Dempke, 2001, Cyclooxygenase-2: a novel target for cancer chemotherapy?, J. Cancer Res. Clin. Oncol., 127, 411, 10.1007/s004320000225

Robak, 2008, The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies, Leuk. Lymphoma, 2, 1

Wang, 2008, Pro-inflammatory prostaglandins and progression of colorectal cancer, Cancer Lett., 267, 197, 10.1016/j.canlet.2008.03.004

Agrawal, 2008, NSAIDs and breast cancer: a possible prevention and treatment strategy, Int. J. Clin. Pract., 62, 444, 10.1111/j.1742-1241.2007.01668.x

Riccioni, 2007, Antileukotriene drugs: clinical application, effectiveness and safety, Curr. Med. Chem., 14, 1966, 10.2174/092986707781368522

Ihara, 2007, Blockade of leukotriene signalling pathway induces apoptosis and suppresses cell proliferation in colon cancer, J. Pharmacol. Sci., 103, 24, 10.1254/jphs.FP0060651

Bertagnolli, 2006, Celecoxib for the prevention of sporadic colorectal adenomas, N. Engl. J. Med., 355, 873, 10.1056/NEJMoa061355

Kapoor, 2008, Atorvastatin and celecoxib: a future role in cancer chemoprevention, Int. J. Cancer, 123, 737, 10.1002/ijc.23534

Sandler, 2004, COX-2 inhibition and lung cancer, Semin. Oncol., 31, 45, 10.1053/j.seminoncol.2004.03.045

Bombardier, 2000, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N. Engl. J. Med., 343, 1520, 10.1056/NEJM200011233432103